权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

MtDNA damage as a biomarker for environmental mitochondrial toxicity

线粒体 DNA 损伤作为环境线粒体毒性的生物标志物

基本信息

批准号：
8334581
负责人：
J Timothy Greenamyre
金额：
$ 34.09万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-09-19 至 2016-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8334581
关键词：
Acute Affect Bacterial Toxins Biological Biological Assay Biological Markers Blood Brain Brain region Cell Death Cessation of life Clinical Collection Complex DNA DNA Damage Data Defect Degenerative Disorder Development Disease Dose Drug Kinetics Drug or chemical Tissue Distribution Electron Transport Environmental Exposure Enzyme Inhibition Epidemiologic Studies Excretory function Exposure to Fishes Genetic Heterogeneity Home environment Human Impairment Insecticides Lead Membrane Metabolism Metals Mitochondria Mitochondrial DNA Mitochondrial Diseases Mitochondrial Proteins Modeling Molecular Muscle Mutation Mycotoxins Nerve Degeneration Nuclear Parkinson Disease Peripheral Pesticides Phenotype Physiological Property Rattus Resistance Risk Factors Rotenone Sampling Skeletal Muscle Solvents Substantia nigra structure Symptoms Syndrome Testing Time Tissues Toxic Environmental Substances Toxic effect Toxin Vegetables base clinical phenotype disease diagnosis dopamine system genetic association inhibitor/antagonist interest killings mitochondrial dysfunction pre-clinical response sample collection

项目摘要

Demonstrating or verifying a current or past exposure to an environmental mitochondrial toxin is extraordinarily difficult. For any given toxin, tissue distribution and pharmacokinetics of the toxin may be unknown. Low-level exposure may not produce a clinical phenotype, and depending on the assay chosen, functional mitochondrial impairment or enzyme inhibition may not persist beyond the acute exposure (or metabolism/excretion of the toxin). Thus, there is a pressing need to develop a biomarker for exposure to environmental mitochondrial inhibitors that is (i) sensitive, (i) at least semi- quantitative, (iii) enduring after toxin exposure has ceased, (iv) stable after specimen collection, and (v) highly reproducible. Another problem is that after exposure to certain mitochondrial toxins, some tissues are selectively vulnerable to damage while others are resistant. For example, when rats are exposed to rotenone chronically, they develop selective degeneration of the nigrostriatal dopamine system similar to Parkinson disease. The molecular and physiological basis for such heterogeneity in biological response is obscure and no biomarker of selective vulnerability exists. Our preliminary data suggest that mtDNA damage in blood or skeletal muscle may provide a biomarker of past or ongoing toxin exposure, and nuclear DNA (nDNA) damage may be a preclinical biomarker of selective vulnerability. For these studies, we will use an extremely sensitive PCR-based assay of DNA damage (both mtDNA & nDNA) that simultaneously allows assessment of multiple forms of damage, and further allows assessment of mtDNA and nDNA damage in the same samples, without a need for mitochondrial isolation. The Specific Aims of this proposal are: 1. (a) Determine how soon after rotenone exposure mtDNA damage can be detected in blood and muscle. (b) Determine the duration, after a single exposure, that mtDNA damage can be detected. 2. Determine the minimal level of complex I inhibition that is required to cause detectable mtDNA damage. 3. Determine whether nuclear DNA (nDNA) damage is a marker of tissues that are selectively vulnerable to mitochondrial toxin-induced degeneration.!! 4. (a) Determine whether peripheral mtDNA damage is a common feature of systemically active complex I inhibitors. (b) Determine whether mtDNA damage is a common feature of other ETC inhibitors, including those acting at complexes II-IV. Preliminary results suggest our assay will provide a biomarker that is relatively simple, extremely sensitive, quantitative, enduring after exposure has ceased, stable after collection, and highly reproducible.

证明或验证当前或过去暴露于环境线粒体毒素是异常困难。对于任何给定的毒素，毒素的组织分布和药代动力学可能未知。低水平暴露可能不会产生临床表型，具体取决于检测选择，功能性线粒体损伤或酶抑制可能不会持续超过急性期暴露（或毒素的代谢/排泄）。因此，迫切需要开发一种生物标志物对于暴露于（i）敏感的环境线粒体抑制剂，（i）至少半敏感定量，(iii) 毒素暴露停止后持久，(iv) 样本采集后稳定，以及 (v) 高度可重复。另一个问题是，在接触某些线粒体毒素后，一些组织选择性地容易受到损害，而其他组织则具有抵抗力。例如，当老鼠长期接触鱼藤酮，它们会发生黑质纹状体多巴胺的选择性变性类似于帕金森病的系统。这种异质性的分子和生理学基础生物反应是模糊的，并且不存在选择性脆弱性的生物标志物。我们的初步数据表明，血液或骨骼肌中的 mtDNA 损伤可能提供生物标志物过去或现在的毒素暴露，核 DNA (nDNA) 损伤可能是选择性脆弱性的临床前生物标志物。对于这些研究，我们将使用极其基于 PCR 的 DNA 损伤（mtDNA 和 nDNA）灵敏检测，同时允许评估多种形式的损伤，并进一步允许评估 mtDNA 和 nDNA 损伤在相同的样品中，无需进行线粒体分离。该提案的具体目标是： 1. (a) 确定鱼藤酮暴露后多长时间可以在血液和肌肉。 (b) 确定单次暴露后可检测到 mtDNA 损伤的持续时间。 2. 确定引起可检测到的 mtDNA 所需的复合物 I 抑制的最低水平损害。 3. 确定核 DNA (nDNA) 损伤是否是选择性损伤组织的标志容易受到线粒体毒素引起的变性。！！ 4. (a) 确定外周 mtDNA 损伤是否是系统性活动的共同特征复合物 I 抑制剂。 (b) 确定mtDNA损伤是否是其他ETC的共同特征抑制剂，包括作用于复合物 II-IV 的抑制剂。初步结果表明我们的测定将提供一种相对简单、极其灵敏、定量、接触停止后持久、收集后稳定、高度可重现。